A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Inclusion criteria

• Subjects aged 20 to 70 years
• Essential hypertension subjects who are measured more 135/85 mmHg of average Diastolic Blood pressure (DBP) and Systolic Blood pressure (SBP) measured by ABP monitor at baseline visit(day 0)
• Subjects who agreed to participate in this study and submitted the written informed consent
• Subjects who considered to understand this study, be cooperative, and able to be followed-up whole of the study period

Exclusion criteria

• Severe hypertension patients; more 180 mmHg of mean sitting SBP and/or more 110 mmHg of mean sitting DBP measured as an office Blood pressure (BP), before Randomization (Screening visit, Placebo run-in visit, Pre-Baseline visit, Baseline visit)
• Patients with difference of office BP at selected one arm over DBP 10 mmHg and/or SBP 20 mmHg at screening visit
• Patients with secondary hypertension
• Patients with symptomatic orthostatic hypotension
• Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c > 9%, increased regimen of oral hypoglycemic agent, using insulin at baseline visit)
• Patients with severe heart disease, ischemic heart disease within 6 months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)
• Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
• Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease
• Patients with severe cerebrovascular disease within 6 months
• Patients with known severe or malignancy retinopathy within 6 months
• Patients with wasting disease, autoimmune disease, connective tissue disease
• Patients with significant investigations - abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function (Aspartate Transaminase(AST), Alanine Transaminase(ALT) more 2 times than upper normal)
• Patients with surgical or medical disease which is able to be affect to absorption, distribution, metabolism, excretion
• Patients with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded 5.5mmol/L)
• Patients with depletion of body fluid or sodium ion not able to correct
• Patients with suspected or history of drug or alcohol abuse within the past two years
• Childbearing, breast-feeding women and female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
• Patients with any chronic inflammation disease needed to chronic inflammation therapy
• Patients with hepatitis type B or type C and carriers
• Patients with laboratory test results indicating clinically significant abnormal results
• Patients receiving medication that can affect blood pressure
• Patients with history of allergic reaction to any angiotensin II antagonist
• Patients with the medical histories of malignant tumor within 5years, except local basal cell carcinoma of the skin
• Patients who took investigational drug within 12 weeks from screening visit or is going on the progress of other clinical trial
• Subject who are judged unsuitable to participate in this study by investigator